Universally optimal crossover designs for the estimation of mixed-carryover effects with an application to biosimilar development
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Discussion Paper / SFB823 ; 3/2018
- Schlagwort
-
Versuchsplanung
Carry over Effect
Arzneimittel
- Ereignis
-
Veröffentlichung
- (wo)
-
Dortmund
- (wer)
-
Universitätsbibliothek Dortmund
- (wann)
-
2018
- Urheber
- Handle
-
2003/36785
- URN
-
urn:nbn:de:101:1-2018060103593373005425
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mielke, Johanna
- Kunert, Joachim
- Universitätsbibliothek Dortmund
Entstanden
- 2018
Ähnliche Objekte (12)
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation
MYL-1402O: A Bevacizumab Biosimilar
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation
MYL-1402O: A Bevacizumab Biosimilar
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation